Cargando…

Safety of SARS-CoV-2 vaccines in patients with chronic myeloid leukemia: a multicenter survey in China

Detalles Bibliográficos
Autores principales:	Yang, Yunfan, Zhang, Yanli, Jiang, Qian, Meng, Li, Li, Weiming, Liu, Bingcheng, Liu, Xiaoli, Zhou, Li, Liang, Rong, Zhu, Xiaojian, NaXu, Kuang, Pu, Lin, Ting, Zhu, Huanling
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9481427/ https://www.ncbi.nlm.nih.gov/pubmed/34966029 http://dx.doi.org/10.1097/CM9.0000000000001899

Ejemplares similares

PB1971: A PHASE 1 MULTICENTER OPEN-LABEL DOSE-ESCALATION AND DOSE-EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, EFFICACY OF HS-10382 (TERN-70) IN CHRONIC MYELOID LEUKEMIA PATIENTS
por: LI, Weiming, et al.
Publicado: (2023)

Mental Health in Persons With Chronic Myeloid Leukemia During the SARS-CoV-2 Pandemic: The Need for Increased Access to Health Care Services
por: Bao, Mei, et al.
Publicado: (2021)

Quality‐of‐life, mental health, and perspective on TKI dose reduction as a prelude to discontinuation in chronic phase chronic myeloid leukemia
por: Chen, Yilin, et al.
Publicado: (2023)

Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial
por: Jiang, Qian, et al.
Publicado: (2022)

Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial
por: Jiang, Qian, et al.
Publicado: (2022)

Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial
por: Jiang, Qian, et al.
Publicado: (2023)

PB1968: IMPACTS ON OUTCOMES AND A PREDICTIVE MODEL OF SEVERE THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC PHASE CHRONIC MYELOID LEUKEMIA RECEIVING INITIAL NILOTINIB-THERAPY
por: LI, Ziyu, et al.
Publicado: (2023)

Acute Myeloid Leukemia Masquerading as Acute Appendicitis
por: Shen, Kai, et al.
Publicado: (2017)

Plerixafor as a preemptive or salvage therapy for healthy donors with poor mobilization of hematopoietic stem cells
por: Kuang, Pu, et al.
Publicado: (2022)

AMLnet, A deep-learning pipeline for the differential diagnosis of acute myeloid leukemia from bone marrow smears
por: Yu, Zebin, et al.
Publicado: (2023)

Impact of blood count recovery on outcomes of acute myeloid leukemia patients achieving morphologic leukemia-free state
por: Cheng, Wen-Yan, et al.
Publicado: (2018)

Heterogeneous prognosis among KIT mutation types in adult acute myeloid leukemia patients with t(8;21)
por: Qin, Ya-Zhen, et al.
Publicado: (2018)

The immunometabolic landscape of the bone marrow microenvironment in acute myeloid leukemia
por: Xu, Binyan, et al.
Publicado: (2022)

Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice
por: Garcia-Gutiérrez, Valentín, et al.
Publicado: (2021)

High efficacy of Azacitidine plus HAG in acute myeloid leukemia: an open-label, single-arm, multi-center, phase 2 study
por: Li, Jun, et al.
Publicado: (2022)

Identification of a novel NPM1 mutation in acute myeloid leukemia
por: Yao, Yiyi, et al.
Publicado: (2023)

The clinical impact of IKZF1 mutation in acute myeloid leukemia
por: Zhang, Xiang, et al.
Publicado: (2023)

Plasmacytoid Dendritic Cells Proliferation Coexisted with Acute Myeloid Leukemia
por: Wang, Min, et al.
Publicado: (2018)

Targeting STAT3-VISTA axis to suppress tumor aggression and burden in acute myeloid leukemia
por: Mo, Jianshan, et al.
Publicado: (2023)

Characteristic immunophenotype and gene co-mutational status orchestrate to optimize the prognosis of CEBPA mutant acute myeloid leukemia
por: Chen, Xinjie, et al.
Publicado: (2023)

JOSD2 regulates PKM2 nuclear translocation and reduces acute myeloid leukemia progression
por: Lei, Hu, et al.
Publicado: (2022)

Molecular predictors of post-transplant survival in acute myeloid leukemia
por: Qin, Tong, et al.
Publicado: (2017)

Genomic landscape of hyperleukocytic acute myeloid leukemia
por: Largeaud, Laetitia, et al.
Publicado: (2022)

Integrative molecular subtypes of acute myeloid leukemia
por: Mo, Qianxing, et al.
Publicado: (2023)

Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib
por: Ottmann, Oliver, et al.
Publicado: (2018)

DLC1 deficiency at diagnosis predicts poor prognosis in acute myeloid leukemia
por: Li, Xueqian, et al.
Publicado: (2022)

CD7-directed CAR T-cell therapy: a potential immunotherapy strategy for relapsed/refractory acute myeloid leukemia
por: Cao, Xuanqi, et al.
Publicado: (2022)

Prognostic impacts and dynamic changes of cohesin complex gene mutations in de novo acute myeloid leukemia
por: Tsai, Cheng-Hong, et al.
Publicado: (2017)

Impact of Covid-19 on the treatment of acute myeloid leukemia
por: Ferrara, Felicetto, et al.
Publicado: (2020)

Orthodontic treatment for a patient with acute myeloid leukemia
por: Hsin-Chung Cheng, Johnson, et al.
Publicado: (2022)

Morphologic leukemia-free state in acute myeloid leukemia is sufficient for successful allogeneic hematopoietic stem cell transplant
por: Pabon, Cindy M., et al.
Publicado: (2021)

Observation and treatment in DDX41-mutated acute myeloid leukemia and myelodysplastic syndrome
por: Al-Kali, Aref, et al.
Publicado: (2023)

Complete response of myeloid/lymphoid neoplasms with PDGFRA rearrangement presenting as leukemia/myeloid sarcoma to imatinib monotherapy
por: Ma, Rui, et al.
Publicado: (2019)

Impact of emerging ACA on survival in chronic myeloid leukemia (CML)
por: Hehlmann, Rüdiger, et al.
Publicado: (2022)

Outcomes of allogeneic transplant in patients with DDX41 mutated myelodysplastic syndrome and acute myeloid leukemia
por: Baranwal, Anmol, et al.
Publicado: (2022)

Signaling mechanisms that regulate ex vivo survival of human acute myeloid leukemia initiating cells
por: Bhavanasi, Dheeraj, et al.
Publicado: (2017)

Rare variants in Fanconi anemia genes are enriched in acute myeloid leukemia
por: Maung, Kyaw Ze Ya, et al.
Publicado: (2018)

B Cell Deficiency in Patients with Relapsed and Refractory Acute Myeloid Leukemia
por: Goswami, Meghali, et al.
Publicado: (2020)

Asciminib in chronic myeloid leukemia: many questions still remain to be answered
por: Eşkazan, Ahmet Emre
Publicado: (2021)

Case Report: Multi-Omics Analysis and CAR-T Treatment of a Chronic Myeloid Leukemia Blast Crisis Case 5 Years After the Discontinuation of TKI
por: Miao, Ya-Ru, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_h7mft7bqa6o9ivlif59464mlfa